Patent Reform | Association for Accessible Medicines
In the News - AAM CEO Dan Leonard shares the industry's 2021 outlook with Chain Drug Review.

Patent Reform

AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Karin Hessler, Assistant General Counsel at the Association for Accessible Medicines, urges attendees to add their voice to the discussion at the one essential generic and biosimilar conference of the year: GRx+Biosims 2019, November 4—6 in Bethesda, MD.

The conference legal track:

Intellectual Property & Patent Reform

AAM opposes abuses of the patent system by brand-name drug companies, and we advocate for patent reform that lends itself to timely patient access to safe, effective and more-affordable medicines for patients in the United States.

AAM: Congress Should Reject Hatch-Waxman Integrity Act of 2019

WASHINGTON, DC (February 7, 2019) —Generic and biosimilar manufacturers rely on FDA approval to operate their businesses—but the Hatch-Waxman Integrity Act requires that to get it, they must surrender their right to question the validity of suspect drug patents. The Administration and Congress have been vocal about enhancing generic and biosimilar competition to lower prescription drug prices.

Subscribe to Patent Reform

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.